Evonik Industries Posts Q2 Earnings: Revenue Down 11%, Adjusted EBITDA Declines 12%

Evonik Industries reported Q2 adjusted EBITDA of €509 million, down 12% YoY, and revenue of €3.5 billion, a 11% decline from the same period last year. The adjusted EBITDA margin remained at 14.5%.

Evonik Industries reported its second-quarter (Q2) 2025 financial results, showing a 12% year-over-year (YoY) decline in adjusted EBITDA to €509 million and a 11% drop in revenue to €3.5 billion. The adjusted EBITDA margin remained steady at 14.5% [1].

The company's Custom Solutions segment saw a 7% decrease in revenue to €1.37 billion, while the Advanced Technologies segment experienced a 1% sales drop to €1.51 billion. The overall revenue decline was influenced by unfavorable currency effects and the divestment of the superabsorbents business. Longer maintenance shutdowns for polyamide 12 and other products also contributed to the revenue decline [1].

Evonik expects its adjusted EBITDA for 2025 to range between €2.0 billion and €2.3 billion, assuming no further global economic weakening. The company plans to reduce capital expenditures by €100 million to €750 million to maintain a cash conversion rate of around 40%. The return on capital employed is expected to align with the previous year's 7.1% [1].

Exponent Expo, a consulting firm specializing in engineering and scientific problem-solving, reported its Q2 fiscal 2025 results, showing a 1% increase in revenue to $142.0 million, despite a 8.8% decrease in diluted EPS to $0.52. While revenue edged up, profitability narrowed, with EBITDA and net income both declining year over year due to rising operating costs. The company expects revenue before reimbursements to be down in the low-single digits and EBITDA margin to be 26.0% to 27.0% of revenues before reimbursements in Q2 FY2025 and for FY2025 [2].

References:
[1] https://chemxplore.com/news/weak-quarter-at-evonik-due-to-declining-demand
[2] https://www.nasdaq.com/articles/exponent-expo-q2-revenue-rises-1